Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Go back to Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy| Pfizer Inc. (NYSE: PFE) | Delayed: 28.07 -0.23 (0.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.30 | 52 Week High | $37.39 | |||
| Open | $27.97 | 52 Week Low | $28.25 | |||
| Day High | $28.18 | P/E | 17.01 | |||
| Day Low | $27.83 | EPS | $1.65 | |||
| Volume | 13,071,077 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 3,500 | |||||
